Literature DB >> 9065612

p53 protein expression in ductal carcinoma in situ (DCIS) of the breast.

P B Rajan1, D J Scott, R H Perry, C D Griffith.   

Abstract

Abnormalities in p53 gene expression have been implicated in many inherited and sporadic forms of malignancies in humans. Immunohistochemical staining using monoclonal antibody D0-7 for the p53 protein expression was performed in 81 cases of pure DCIS, 14 benign breast lesions and 2 cases with normal breast tissue. Expression of p53 protein was detected in 15 (18.5%) cases of pure DCIS. Thirteen (25%) of the 52 comedo type DCIS showed p53 protein expression compared with 2 (6.9%) of the 29 non-comedo types (P < 0.02). p53 protein expression was also associated with high nuclear grade (P < 0.001) and high mitotic index (P < 0.05). The pattern of p53 protein staining was diffuse in one comedo type DCIS, regional in 6 comedo types, and focal in the remaining 8 cases (6 comedo type and 2 micropapillary type DCIS). The patient with comedo type DCIS showing diffuse staining has a family history of breast cancer in the first and second degree relatives (sister and maternal aunt). Clinical follow-up data was available in 52 cases. Follow-up period ranged from 9 to 55 months. Three patients, who were primarily treated by local excision, have had a documented local recurrence in the form of residual tumor within a short interval of 5 to 11 months. In all these three patients both the original and the recurrent tumors are negative for p53 protein expression. The difference in the local recurrence rate between p53 positive (0/15) and p53 negative (3/37) cased does not reach statistical significance (p > 0.05). We interpret that the local tumor recurrence in these three cases within a short period after primary excision is due to the presence of residual tumor at the excision site and is independent of the p53 gene alteration. It is concluded that p53 protein expression in DCIS is associated with comedo subtype, high nuclear grade, and high mitotic index, and is a promising new parameter to evaluate the cellular biology and prognosis of DCIS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065612     DOI: 10.1023/a:1005741723479

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

Review 1.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

2.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 3.  Is loss of p53 a driver of ductal carcinoma in situ progression?

Authors:  Rhiannon L Morrissey; Alastair M Thompson; Guillermina Lozano
Journal:  Br J Cancer       Date:  2022-06-28       Impact factor: 7.640

4.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

Review 5.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

6.  Array-based multiplex analysis of DNA methylation in breast cancer tissues.

Authors:  Anatoliy A Melnikov; Denise M Scholtens; Elizabeth L Wiley; Seema A Khan; Victor V Levenson
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

7.  Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer?

Authors:  Leopoldo Costarelli; Domenico Campagna; Maria Mauri; Lucio Fortunato
Journal:  Int J Surg Oncol       Date:  2012-05-10

8.  A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk.

Authors:  Geoffrey C Kabat; Rita A Kandel; Andrew G Glass; Joan G Jones; Neal Olson; Catherine Duggan; Mindy Ginsberg; Abdissa Negassa; Thomas E Rohan
Journal:  J Oncol       Date:  2011-08-22       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.